History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ?12 months prior to randomization
No history of serious digestive and/or absorptive problems, including inflammatory bowel disease and chronic diarrhea that preclude adherence to the study diet
Have inflammatory bowel disease for which the participant has used immunosuppressive agents within the last 2 years.
Active diarrhea or inflammatory bowel disease
Active or documented inflammatory disease.
Patients with history of and/or active inflammatory bowel disease.
Participants with inflammatory bowel disease
Active inflammatory or other gastrointestinal disease,
Inflammatory or chronic functional bowel disorder such as Crohn's Disease, inflammatory bowel disease, chronic diarrhea, or constipation
History of inflammatory bowel disease
History of inflammatory bowel disease
History of inflammatory bowel disease, autoimmune disease, or other connective tissue diseases
Patients with history or current diagnosis of inflammatory bowel disease are not eligible
Any condition or history of active rectal inflammatory bowel disease or other factors which might increase the risk of fistula formation;
Active inflammatory bowel disease, other bowel disease causing chronic diarrhea (defined as > 4 loose stools per day), or bowel obstruction
Inflammatory bowel disease
Patients with inflammatory bowel disease
Patients with inflammatory bowel disease
Active or prior documented inflammatory bowel disease
History of inflammatory bowel disease;
malabsorption syndromes such as celiac disease, cystic fibrosis, inflammatory bowel disease, systemic sclerosis, and carcinoid syndrome
History of hemorrhagic diarrhea, inflammatory bowel disease or active uncontrolled peptic ulcer disease; (concomitant therapy with ranitidine or its equivalent and/or omeprazole or its equivalent is acceptable); history of ileus or other significant gastrointestinal disorder known to predispose to ileus or chronic bowel hypomotility
Inflammatory bowel disease
Patients with complete bowel obstruction or who are at high risk for gastrointestinal (GI) perforation or severe hemorrhage and patients with inflammatory bowel disease
Clinical contraindication to stereotactic body radiotherapy as determined by the investigator (e.g., active systemic sclerosis, active inflammatory bowel disease if bowel is within radiation field)
Poorly controlled inflammatory bowel disease
History of inflammatory bowel disease
Uncontrolled inflammatory bowel disease
Autoimmune disease such as scleroderma, lupus, or inflammatory bowel disease
History of autoimmune disease such as scleroderma, lupus, and inflammatory bowel disease
Patients with active inflammatory bowel disease
Patients with inflammatory bowel disease
History of inflammatory bowel disease
Has active or prior inflammatory bowel disease or primary immunodeficiency
There are no exclusions due to co-morbid disease or illnesses except for patients who carry a diagnosis of Inflammatory Bowel Disease that has been active within the last year
History of inflammatory bowel disease
History of or ongoing inflammatory bowel disease
Any medical condition that would be a contra-indication to radiation therapy, such as inflammatory bowel disease
Patients must not have a history of inflammatory bowel disease or diverticulitis (history of diverticulosis is allowed)
No standard contraindications to radiation therapy including prior significant radiation therapy, inflammatory bowel disease, irritable bowel syndrome or collagen vascular disease
Patients with significantly diseased or obstructed gastrointestinal tract that could interfere with absorption of oral medication, including inflammatory or chronic functional bowel disorder, such as Crohn disease, inflammatory bowel disease, chronic diarrhea, or constipation
History of inflammatory bowel disease requiring ongoing therapy
DONOR: History of or symptoms consistent with inflammatory bowel disease or a serious autoimmune disorder
Inflammatory bowel disease
Active inflammatory bowel disease
Patients with history of inflammatory bowel disease, or who require steroid or cytotoxic therapy for collagen vascular disease
Patients must not have a history of inflammatory bowel disease or diverticulitis (history of diverticulosis is allowed)
Patients with active inflammatory bowel disease
The participant has a history of inflammatory bowel disease or Crohn's disease requiring medical intervention within 12 months.
Patient must not have a history of inflammatory bowel disease requiring pharmacological and/or surgical intervention within the 12 months prior to randomization
Patient must have no active inflammatory bowel disease
Severe gastrointestinal conditions such as clinical or radiological evidence of bowel obstruction within 4 weeks prior to study entry, uncontrolled diarrhea in the last 4 weeks prior to enrollment, or history of inflammatory bowel disease.
Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or any upper gastrointestinal surgery including gastric resection.
Ongoing inflammatory bowel disease
History of inflammatory bowel disease
Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or upper gastrointestinal surgery including gastric resection
History of inflammatory bowel disease or active bowel inflammation
History of inflammatory bowel disease, prior bowel surgeries (or colostomy) for any reason, or prior partial/radical cystectomy for any reason
have active gastrointestinal (GI) disease characterized by inflammatory bowel disease, malabsorption syndrome, or frequent Grade 2 or more diarrhea
Inflammatory bowel disease
Have a history of inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ?12 months prior to randomization.
Clinical contraindication to stereotactic body radiotherapy (e.g. active systemic sclerosis, active inflammatory bowel disease if bowel is within target field, etc)
History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) =< 12 months prior to randomization
Active inflammatory bowel disease
Inflammatory bowel disease
Inflammatory bowel disease or connective tissue disease requiring medical management
History of autoimmune disease, including inflammatory bowel disease
History of inflammatory bowel disease
Prior history of scleroderma or inflammatory bowel disease
Clinical contraindication to stereotactic body radiotherapy (e.g. active systemic sclerosis, active inflammatory bowel disease if bowel is within target field, etc)
Any chronic inflammatory bowel disease and/or chronic bowl obstruction
history of inflammatory bowel disease of the rectum;
Ongoing inflammatory bowel disease
History of autoimmune disease or known inflammatory bowel disease.
History of inflammatory bowel disease
Patients with a history of inflammatory bowel disease
Ongoing inflammatory bowel disease
Patients with history of inflammatory bowel disease or major bowel surgery
Ongoing gastrointestinal medical condition such as Crohn's disease, Inflammatory bowel disease, chronic diarrhea, or constipation
Ongoing inflammatory bowel disease
Known clinically significant gastrointestinal disease including, but not limited to, inflammatory bowel disease
Active or prior documented autoimmune, or inflammatory bowel disease, or inflammatory bowel disease. or systemic treatment for psoriasis within the past 5 years.;
Known clinically significant gastrointestinal disease including, but not limited to, inflammatory bowel disease
Ongoing inflammatory bowel disease
Active inflammatory bowel disease
Subjects with known clinically significant gastrointestinal disease including, but not limited to, inflammatory bowel disease
Known clinically significant gastrointestinal disease including, but not limited to, inflammatory bowel disease
Patients with active inflammatory bowel disease
Known clinically significant gastrointestinal disease including, but not limited to, inflammatory bowel disease
Prior history of inflammatory bowel disease.
Patients with inflammatory bowel disease or other autoimmune conditions which might affect the radiated colon or rectum
Gastrointestinal (GI) disease with increased risk of diarrhea (e.g. inflammatory bowel disease)
History of or active inflammatory bowel disease or active bowel inflammation
History of inflammatory bowel disease
Gastro-intestinal disease with increased risk of diarrhea (e.g. inflammatory bowel disease)
Gastrointestinal (GI) disease with increased risk of diarrhea [e.g. inflammatory bowel disease (IBD)]
Active inflammatory bowel disease or other bowel disease causing chronic diarrhea.
Patients with inflammatory or chronic functional bowel disorder, such as Crohn disease, inflammatory bowel disease, or gastrointestinal graft versus host disease that in the opinion of the investigator may interfere with absorption of ponatinib or increase the risk of serious complications
Have a history (within 3 years) of inflammatory bowel disease,
History of inflammatory bowel disease
History of or active inflammatory disease or active bowel inflammation
Severe gastrointestinal conditions such as clinical or radiological evidence of bowel obstruction within 4 weeks prior to study entry, uncontrolled diarrhea in the last 4 weeks prior to enrollment, or history of inflammatory bowel disease
Patients with gastrointestinal disease or disorder that could interfere with absorption of CUDC-907, such as bowel obstruction or inflammatory bowel disease
History of clinically significant Crohnâ€™s disease or inflammatory bowel disease (IBD)
Any history of inflammatory bowel disease
Prior history of inflammatory bowel disease or other chronic diarrheal illness
Clinically significant systemic infection or uncontrolled chronic inflammatory disease (eg, rheumatoid arthritis, inflammatory bowel disease) as determined by the investigator during screening.
Inflammatory bowel disease (IBD)/Crohn's
Patients with a history of gastric bypass surgery or inflammatory bowel disease
Prior colorectal surgery or history of inflammatory bowel disease
Any history of inflammatory bowel disease
Patients with inflammatory bowel disease
Diagnosis of inflammatory bowel disease, liver or kidney disease, bleeding diathesis
No history of Inflammatory bowel disease
Individuals with inflammatory bowel disease
Participants with dysplasia-associated mass or lesion (DALM) due to longstanding idiopathic inflammatory bowel disease will be excluded
Inflammatory bowel disease
Has severe colitis of any etiology or a history of inflammatory bowel disease (IBD)
Diagnosis of inflammatory bowel disease
Serious digestive and/or absorptive problems, including inflammatory bowel disease and chronic diarrhea that preclude adherence to the study diet.
Personal history of inflammatory bowel disease
History of CRC, bowel resection, polyposis syndrome, or inflammatory bowel disease
Contraindications to radiotherapy (including active inflammatory bowel disease).
Active inflammatory bowel disease within the last 6 months
Patients with active inflammatory bowel disease
Active inflammatory bowel disease within the last 6 months
Any active cancer, history of gastrointestinal cancer, or chronic disease such as peptic ulcer, irritable bowel syndrome, inflammatory bowel disease, intestinal malabsorption syndrome or other gastrointestinal disorder
Self-reported inflammatory bowel disease
No history of inflammatory bowel disease
History of inflammatory bowel disease
Has a history of inflammatory bowel disease or history of scleroderma
History of inflammatory bowel disease.
